#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


Text=Affinity States of Striatal Dopamine D2 Receptors in Antipsychotic-Free Patients with Schizophrenia Abstract Background Dopamine D2 receptors are reported to have high-affinity (D2High) and low-affinity (D2Low) states.
1-1	0-8	Affinity	_
1-2	9-15	States	_
1-3	16-18	of	_
1-4	19-27	Striatal	_
1-5	28-36	Dopamine	_
1-6	37-39	D2	_
1-7	40-49	Receptors	_
1-8	50-52	in	_
1-9	53-71	Antipsychotic-Free	http://maven.renci.org/NeuroBridge/neurobridge#Unmedicated
1-10	72-80	Patients	http://maven.renci.org/NeuroBridge/neurobridge#Unmedicated
1-11	81-85	with	http://maven.renci.org/NeuroBridge/neurobridge#Unmedicated
1-12	86-99	Schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Unmedicated
1-13	100-108	Abstract	http://maven.renci.org/NeuroBridge/neurobridge#Unmedicated
1-14	109-119	Background	_
1-15	120-128	Dopamine	_
1-16	129-131	D2	_
1-17	132-141	receptors	_
1-18	142-145	are	_
1-19	146-154	reported	_
1-20	155-157	to	_
1-21	158-162	have	_
1-22	163-176	high-affinity	_
1-23	177-178	(	_
1-24	179-185	D2High	_
1-25	186-187	)	_
1-26	188-191	and	_
1-27	192-204	low-affinity	_
1-28	205-206	(	_
1-29	207-212	D2Low	_
1-30	213-214	)	_
1-31	215-221	states	_
1-32	222-223	.	_

Text=Although an increased proportion of D2High has been demonstrated in animal models of schizophrenia, few clinical studies have investigated this alteration of D2High in schizophrenia in vivo.
2-1	224-232	Although	_
2-2	233-235	an	_
2-3	236-245	increased	_
2-4	246-256	proportion	_
2-5	257-259	of	_
2-6	260-266	D2High	_
2-7	267-270	has	_
2-8	271-275	been	_
2-9	276-288	demonstrated	_
2-10	289-291	in	_
2-11	292-298	animal	_
2-12	299-305	models	_
2-13	306-308	of	_
2-14	309-322	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
2-15	323-324	,	_
2-16	325-328	few	_
2-17	329-337	clinical	_
2-18	338-345	studies	_
2-19	346-350	have	_
2-20	351-363	investigated	_
2-21	364-368	this	_
2-22	369-379	alteration	_
2-23	380-382	of	_
2-24	383-389	D2High	_
2-25	390-392	in	_
2-26	393-406	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
2-27	407-409	in	_
2-28	410-414	vivo	_
2-29	415-416	.	_

Text=Methods Eleven patients with schizophrenia, including 10 antipsychotic-naive and 1 antipsychotic-free individuals, and 17 healthy controls were investigated.
3-1	417-424	Methods	_
3-2	425-431	Eleven	_
3-3	432-440	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
3-4	441-445	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
3-5	446-459	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
3-6	460-461	,	_
3-7	462-471	including	_
3-8	472-474	10	_
3-9	475-494	antipsychotic-naive	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
3-10	495-498	and	_
3-11	499-500	1	_
3-12	501-519	antipsychotic-free	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
3-13	520-531	individuals	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
3-14	532-533	,	_
3-15	534-537	and	_
3-16	538-540	17	_
3-17	541-548	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
3-18	549-557	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
3-19	558-562	were	_
3-20	563-575	investigated	_
3-21	576-577	.	_

Text=Psychopathology was assessed by Positive and Negative Syndrome Scale, and a 5-factor model was used.
4-1	578-593	Psychopathology	_
4-2	594-597	was	_
4-3	598-606	assessed	_
4-4	607-609	by	_
4-5	610-618	Positive	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
4-6	619-622	and	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
4-7	623-631	Negative	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
4-8	632-640	Syndrome	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
4-9	641-646	Scale	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
4-10	647-648	,	_
4-11	649-652	and	_
4-12	653-654	a	_
4-13	655-663	5-factor	_
4-14	664-669	model	_
4-15	670-673	was	_
4-16	674-678	used	_
4-17	679-680	.	_

Text=Two radioligands, [11C] raclopride and [11C] MNPA, were employed to quantify total dopamine D2 receptor and D2High, respectively, in the striatum by measuring their binding potentials.
5-1	681-684	Two	_
5-2	685-697	radioligands	_
5-3	698-699	,	_
5-4	700-701	[	_
5-5	702-705	11C	_
5-6	706-707	]	_
5-7	708-718	raclopride	_
5-8	719-722	and	_
5-9	723-724	[	_
5-10	725-728	11C	_
5-11	729-730	]	_
5-12	731-735	MNPA	_
5-13	736-737	,	_
5-14	738-742	were	_
5-15	743-751	employed	_
5-16	752-754	to	_
5-17	755-763	quantify	_
5-18	764-769	total	_
5-19	770-778	dopamine	_
5-20	779-781	D2	_
5-21	782-790	receptor	_
5-22	791-794	and	_
5-23	795-801	D2High	_
5-24	802-803	,	_
5-25	804-816	respectively	_
5-26	817-818	,	_
5-27	819-821	in	_
5-28	822-825	the	_
5-29	826-834	striatum	_
5-30	835-837	by	_
5-31	838-847	measuring	_
5-32	848-853	their	_
5-33	854-861	binding	_
5-34	862-872	potentials	_
5-35	873-874	.	_

Text=Binding potential values of [11C] raclopride and [11C] MNPA and the binding potential ratio of [11C] MNPA to [11C] raclopride in the striatal subregions were statistically compared between the 2 diagnostic groups using multivariate analysis of covariance controlling for age, gender, and smoking.
6-1	875-882	Binding	_
6-2	883-892	potential	_
6-3	893-899	values	_
6-4	900-902	of	_
6-5	903-904	[	_
6-6	905-908	11C	_
6-7	909-910	]	_
6-8	911-921	raclopride	_
6-9	922-925	and	_
6-10	926-927	[	_
6-11	928-931	11C	_
6-12	932-933	]	_
6-13	934-938	MNPA	_
6-14	939-942	and	_
6-15	943-946	the	_
6-16	947-954	binding	_
6-17	955-964	potential	_
6-18	965-970	ratio	_
6-19	971-973	of	_
6-20	974-975	[	_
6-21	976-979	11C	_
6-22	980-981	]	_
6-23	982-986	MNPA	_
6-24	987-989	to	_
6-25	990-991	[	_
6-26	992-995	11C	_
6-27	996-997	]	_
6-28	998-1008	raclopride	_
6-29	1009-1011	in	_
6-30	1012-1015	the	_
6-31	1016-1024	striatal	_
6-32	1025-1035	subregions	_
6-33	1036-1040	were	_
6-34	1041-1054	statistically	_
6-35	1055-1063	compared	_
6-36	1064-1071	between	_
6-37	1072-1075	the	_
6-38	1076-1077	2	_
6-39	1078-1088	diagnostic	_
6-40	1089-1095	groups	_
6-41	1096-1101	using	_
6-42	1102-1114	multivariate	_
6-43	1115-1123	analysis	_
6-44	1124-1126	of	_
6-45	1127-1137	covariance	_
6-46	1138-1149	controlling	_
6-47	1150-1153	for	_
6-48	1154-1157	age	_
6-49	1158-1159	,	_
6-50	1160-1166	gender	_
6-51	1167-1168	,	_
6-52	1169-1172	and	_
6-53	1173-1180	smoking	_
6-54	1181-1182	.	_

Text=Correlations between binding potential and Positive and Negative Syndrome Scale scores were also examined.
7-1	1183-1195	Correlations	_
7-2	1196-1203	between	_
7-3	1204-1211	binding	_
7-4	1212-1221	potential	_
7-5	1222-1225	and	_
7-6	1226-1234	Positive	_
7-7	1235-1238	and	http://maven.renci.org/NeuroBridge/neurobridge#PhysicalMeasurement
7-8	1239-1247	Negative	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
7-9	1248-1256	Syndrome	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
7-10	1257-1262	Scale	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
7-11	1263-1269	scores	_
7-12	1270-1274	were	_
7-13	1275-1279	also	_
7-14	1280-1288	examined	_
7-15	1289-1290	.	_

Text=Results Multivariate analysis of covariance demonstrated a significant effect of diagnosis (schizophrenia and control) on the binding potential ratio (P=.018), although the effects of diagnosis on binding potential values obtained with either [11C] raclopride or [11C] MNPA were nonsignificant.
8-1	1291-1298	Results	_
8-2	1299-1311	Multivariate	_
8-3	1312-1320	analysis	_
8-4	1321-1323	of	_
8-5	1324-1334	covariance	_
8-6	1335-1347	demonstrated	_
8-7	1348-1349	a	_
8-8	1350-1361	significant	_
8-9	1362-1368	effect	_
8-10	1369-1371	of	_
8-11	1372-1381	diagnosis	_
8-12	1382-1383	(	_
8-13	1384-1397	schizophrenia	_
8-14	1398-1401	and	_
8-15	1402-1409	control	_
8-16	1410-1411	)	_
8-17	1412-1414	on	_
8-18	1415-1418	the	_
8-19	1419-1426	binding	_
8-20	1427-1436	potential	_
8-21	1437-1442	ratio	_
8-22	1443-1444	(	_
8-23	1445-1451	P=.018	_
8-24	1452-1453	)	_
8-25	1454-1455	,	_
8-26	1456-1464	although	_
8-27	1465-1468	the	_
8-28	1469-1476	effects	_
8-29	1477-1479	of	_
8-30	1480-1489	diagnosis	_
8-31	1490-1492	on	_
8-32	1493-1500	binding	_
8-33	1501-1510	potential	_
8-34	1511-1517	values	_
8-35	1518-1526	obtained	_
8-36	1527-1531	with	_
8-37	1532-1538	either	_
8-38	1539-1540	[	_
8-39	1541-1544	11C	_
8-40	1545-1546	]	_
8-41	1547-1557	raclopride	_
8-42	1558-1560	or	_
8-43	1561-1562	[	_
8-44	1563-1566	11C	_
8-45	1567-1568	]	_
8-46	1569-1573	MNPA	_
8-47	1574-1578	were	_
8-48	1579-1593	nonsignificant	_
8-49	1594-1595	.	_

Text=Posthoc test showed that the binding potential ratio was significantly higher in the putamen of patients (P=.017).
9-1	1596-1603	Posthoc	_
9-2	1604-1608	test	_
9-3	1609-1615	showed	_
9-4	1616-1620	that	_
9-5	1621-1624	the	_
9-6	1625-1632	binding	_
9-7	1633-1642	potential	_
9-8	1643-1648	ratio	_
9-9	1649-1652	was	_
9-10	1653-1666	significantly	_
9-11	1667-1673	higher	_
9-12	1674-1676	in	_
9-13	1677-1680	the	_
9-14	1681-1688	putamen	_
9-15	1689-1691	of	_
9-16	1692-1700	patients	_
9-17	1701-1702	(	_
9-18	1703-1709	P=.017	_
9-19	1710-1711	)	_
9-20	1712-1713	.	_

Text=The Positive and Negative Syndrome Scale “ depressed ” factor in patients was positively correlated with binding potential values of both ligands in the caudate.
10-1	1714-1717	The	_
10-2	1718-1726	Positive	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
10-3	1727-1730	and	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
10-4	1731-1739	Negative	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
10-5	1740-1748	Syndrome	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
10-6	1749-1754	Scale	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
10-7	1755-1756	“	_
10-8	1757-1766	depressed	_
10-9	1767-1768	”	_
10-10	1769-1775	factor	_
10-11	1776-1778	in	_
10-12	1779-1787	patients	_
10-13	1788-1791	was	_
10-14	1792-1802	positively	_
10-15	1803-1813	correlated	_
10-16	1814-1818	with	_
10-17	1819-1826	binding	_
10-18	1827-1836	potential	_
10-19	1837-1843	values	_
10-20	1844-1846	of	_
10-21	1847-1851	both	_
10-22	1852-1859	ligands	_
10-23	1860-1862	in	_
10-24	1863-1866	the	_
10-25	1867-1874	caudate	_
10-26	1875-1876	.	_

Text=Conclusions The present study indicates the possibilities of: (1) a higher proportion of D2High in the putamen despite unaltered amounts of total dopamine D2 receptors; and (2) associations between depressive symptoms and amounts of caudate dopamine D2 receptors in patients with schizophrenia.
11-1	1877-1888	Conclusions	_
11-2	1889-1892	The	_
11-3	1893-1900	present	_
11-4	1901-1906	study	_
11-5	1907-1916	indicates	_
11-6	1917-1920	the	_
11-7	1921-1934	possibilities	_
11-8	1935-1937	of	_
11-9	1938-1939	:	_
11-10	1940-1941	(	_
11-11	1942-1943	1	_
11-12	1944-1945	)	_
11-13	1946-1947	a	_
11-14	1948-1954	higher	_
11-15	1955-1965	proportion	_
11-16	1966-1968	of	_
11-17	1969-1975	D2High	_
11-18	1976-1978	in	_
11-19	1979-1982	the	_
11-20	1983-1990	putamen	_
11-21	1991-1998	despite	_
11-22	1999-2008	unaltered	_
11-23	2009-2016	amounts	_
11-24	2017-2019	of	_
11-25	2020-2025	total	_
11-26	2026-2034	dopamine	_
11-27	2035-2037	D2	_
11-28	2038-2047	receptors	_
11-29	2048-2049	;	_
11-30	2050-2053	and	_
11-31	2054-2055	(	_
11-32	2056-2057	2	_
11-33	2058-2059	)	_
11-34	2060-2072	associations	_
11-35	2073-2080	between	_
11-36	2081-2091	depressive	_
11-37	2092-2100	symptoms	_
11-38	2101-2104	and	_
11-39	2105-2112	amounts	_
11-40	2113-2115	of	_
11-41	2116-2123	caudate	_
11-42	2124-2132	dopamine	_
11-43	2133-2135	D2	_
11-44	2136-2145	receptors	_
11-45	2146-2148	in	_
11-46	2149-2157	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
11-47	2158-2162	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
11-48	2163-2176	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
11-49	2177-2178	.	_

Text=Methods Participants A total of 11 patients with schizophrenia (4 men and 7 women) were recruited from affiliated hospitals or clinics.
12-1	2179-2186	Methods	http://maven.renci.org/NeuroBridge/neurobridge#DataCollectionMethod
12-2	2187-2199	Participants	_
12-3	2200-2201	A	_
12-4	2202-2207	total	_
12-5	2208-2210	of	_
12-6	2211-2213	11	_
12-7	2214-2222	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
12-8	2223-2227	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
12-9	2228-2241	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
12-10	2242-2243	(	_
12-11	2244-2245	4	_
12-12	2246-2249	men	_
12-13	2250-2253	and	_
12-14	2254-2255	7	_
12-15	2256-2261	women	_
12-16	2262-2263	)	_
12-17	2264-2268	were	_
12-18	2269-2278	recruited	_
12-19	2279-2283	from	_
12-20	2284-2294	affiliated	_
12-21	2295-2304	hospitals	_
12-22	2305-2307	or	_
12-23	2308-2315	clinics	_
12-24	2316-2317	.	_

Text=Seventeen healthy controls (8 men and 9 women) were recruited by the National Institute of Radiological Sciences, Chiba, Japan, for participation in this study.
13-1	2318-2327	Seventeen	_
13-2	2328-2335	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
13-3	2336-2344	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
13-4	2345-2346	(	_
13-5	2347-2348	8	_
13-6	2349-2352	men	_
13-7	2353-2356	and	_
13-8	2357-2358	9	_
13-9	2359-2364	women	_
13-10	2365-2366	)	_
13-11	2367-2371	were	_
13-12	2372-2381	recruited	_
13-13	2382-2384	by	_
13-14	2385-2388	the	_
13-15	2389-2397	National	_
13-16	2398-2407	Institute	_
13-17	2408-2410	of	_
13-18	2411-2423	Radiological	_
13-19	2424-2432	Sciences	_
13-20	2433-2434	,	_
13-21	2435-2440	Chiba	_
13-22	2441-2442	,	_
13-23	2443-2448	Japan	_
13-24	2449-2450	,	_
13-25	2451-2454	for	_
13-26	2455-2468	participation	_
13-27	2469-2471	in	_
13-28	2472-2476	this	_
13-29	2477-2482	study	_
13-30	2483-2484	.	_

Text=The patient group was comprised of 10 antipsychotic-naive patients (one had taken benzodiazepines the night before her PET scans) and 1 patient who had been antipsychotic-free for 2 years after 1-year treatment with aripiprazole.
14-1	2485-2488	The	_
14-2	2489-2496	patient	_
14-3	2497-2502	group	_
14-4	2503-2506	was	_
14-5	2507-2516	comprised	_
14-6	2517-2519	of	_
14-7	2520-2522	10	_
14-8	2523-2542	antipsychotic-naive	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
14-9	2543-2551	patients	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
14-10	2552-2553	(	_
14-11	2554-2557	one	_
14-12	2558-2561	had	_
14-13	2562-2567	taken	_
14-14	2568-2583	benzodiazepines	_
14-15	2584-2587	the	_
14-16	2588-2593	night	_
14-17	2594-2600	before	_
14-18	2601-2604	her	_
14-19	2605-2608	PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography
14-20	2609-2614	scans	_
14-21	2615-2616	)	_
14-22	2617-2620	and	_
14-23	2621-2622	1	_
14-24	2623-2630	patient	_
14-25	2631-2634	who	_
14-26	2635-2638	had	_
14-27	2639-2643	been	_
14-28	2644-2662	antipsychotic-free	_
14-29	2663-2666	for	_
14-30	2667-2668	2	_
14-31	2669-2674	years	_
14-32	2675-2680	after	_
14-33	2681-2687	1-year	_
14-34	2688-2697	treatment	_
14-35	2698-2702	with	_
14-36	2703-2715	aripiprazole	_
14-37	2716-2717	.	_

Text=All patients fulfilled the diagnostic criteria for schizophrenia according to DSM-IV.
15-1	2718-2721	All	_
15-2	2722-2730	patients	_
15-3	2731-2740	fulfilled	_
15-4	2741-2744	the	_
15-5	2745-2755	diagnostic	_
15-6	2756-2764	criteria	_
15-7	2765-2768	for	_
15-8	2769-2782	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
15-9	2783-2792	according	_
15-10	2793-2795	to	_
15-11	2796-2802	DSM-IV	_
15-12	2803-2804	.	_

Text=None of the patients were comorbid with other neuropsychiatric disorders or had substance abuse.
16-1	2805-2809	None	_
16-2	2810-2812	of	_
16-3	2813-2816	the	_
16-4	2817-2825	patients	_
16-5	2826-2830	were	_
16-6	2831-2839	comorbid	_
16-7	2840-2844	with	_
16-8	2845-2850	other	_
16-9	2851-2867	neuropsychiatric	_
16-10	2868-2877	disorders	_
16-11	2878-2880	or	_
16-12	2881-2884	had	_
16-13	2885-2894	substance	_
16-14	2895-2900	abuse	_
16-15	2901-2902	.	_

Text=Psychopathology was assessed using the Positive and Negative Syndrome Scale (PANSS), and a 5-factor model was used to calculate PANSS subscale scores (positive, negative, disorganized/concrete, excited, and depressed factors).
17-1	2903-2918	Psychopathology	_
17-2	2919-2922	was	_
17-3	2923-2931	assessed	_
17-4	2932-2937	using	_
17-5	2938-2941	the	_
17-6	2942-2950	Positive	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
17-7	2951-2954	and	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
17-8	2955-2963	Negative	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
17-9	2964-2972	Syndrome	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
17-10	2973-2978	Scale	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
17-11	2979-2980	(	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
17-12	2981-2986	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
17-13	2987-2988	)	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
17-14	2989-2990	,	_
17-15	2991-2994	and	_
17-16	2995-2996	a	_
17-17	2997-3005	5-factor	_
17-18	3006-3011	model	_
17-19	3012-3015	was	_
17-20	3016-3020	used	_
17-21	3021-3023	to	_
17-22	3024-3033	calculate	_
17-23	3034-3039	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
17-24	3040-3048	subscale	_
17-25	3049-3055	scores	_
17-26	3056-3057	(	_
17-27	3058-3066	positive	_
17-28	3067-3068	,	_
17-29	3069-3077	negative	_
17-30	3078-3079	,	_
17-31	3080-3101	disorganized/concrete	_
17-32	3102-3103	,	_
17-33	3104-3111	excited	_
17-34	3112-3113	,	_
17-35	3114-3117	and	_
17-36	3118-3127	depressed	_
17-37	3128-3135	factors	_
17-38	3136-3137	)	_
17-39	3138-3139	.	_

Text=The healthy control volunteers were recruited by public notices.
18-1	3140-3143	The	_
18-2	3144-3151	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
18-3	3152-3159	control	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
18-4	3160-3170	volunteers	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
18-5	3171-3175	were	_
18-6	3176-3185	recruited	_
18-7	3186-3188	by	_
18-8	3189-3195	public	_
18-9	3196-3203	notices	_
18-10	3204-3205	.	_

Text=They had no history of psychiatric disease, neurological injury or disease, severe medical diseases, substance abuse that may affect brain functions, or first-degree relatives suffering from psychotic episodes.
19-1	3206-3210	They	_
19-2	3211-3214	had	_
19-3	3215-3217	no	_
19-4	3218-3225	history	_
19-5	3226-3228	of	_
19-6	3229-3240	psychiatric	_
19-7	3241-3248	disease	_
19-8	3249-3250	,	_
19-9	3251-3263	neurological	_
19-10	3264-3270	injury	_
19-11	3271-3273	or	_
19-12	3274-3281	disease	_
19-13	3282-3283	,	_
19-14	3284-3290	severe	_
19-15	3291-3298	medical	_
19-16	3299-3307	diseases	_
19-17	3308-3309	,	_
19-18	3310-3319	substance	_
19-19	3320-3325	abuse	_
19-20	3326-3330	that	_
19-21	3331-3334	may	_
19-22	3335-3341	affect	_
19-23	3342-3347	brain	_
19-24	3348-3357	functions	_
19-25	3358-3359	,	_
19-26	3360-3362	or	_
19-27	3363-3375	first-degree	_
19-28	3376-3385	relatives	_
19-29	3386-3395	suffering	_
19-30	3396-3400	from	_
19-31	3401-3410	psychotic	_
19-32	3411-3419	episodes	_
19-33	3420-3421	.	_

Text=All the diagnostic interviews and PANSS ratings were conducted by trained psychiatrists.
20-1	3422-3425	All	_
20-2	3426-3429	the	_
20-3	3430-3440	diagnostic	_
20-4	3441-3451	interviews	_
20-5	3452-3455	and	_
20-6	3456-3461	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
20-7	3462-3469	ratings	_
20-8	3470-3474	were	_
20-9	3475-3484	conducted	_
20-10	3485-3487	by	_
20-11	3488-3495	trained	_
20-12	3496-3509	psychiatrists	_
20-13	3510-3511	.	_

Text=Table 1 presents the participants ’ demographic information.
21-1	3512-3517	Table	_
21-2	3518-3519	1	_
21-3	3520-3528	presents	_
21-4	3529-3532	the	_
21-5	3533-3545	participants	_
21-6	3546-3547	’	_
21-7	3548-3559	demographic	_
21-8	3560-3571	information	_
21-9	3572-3573	.	_

Text=This study was approved by the Radiation Drug Safety Committee and the Institutional Review Board of the National Institute of Radiological Sciences, Japan, and was carried out in accordance with the Code of Ethics of the World Medical Association.
22-1	3574-3578	This	_
22-2	3579-3584	study	_
22-3	3585-3588	was	_
22-4	3589-3597	approved	_
22-5	3598-3600	by	_
22-6	3601-3604	the	_
22-7	3605-3614	Radiation	_
22-8	3615-3619	Drug	_
22-9	3620-3626	Safety	_
22-10	3627-3636	Committee	_
22-11	3637-3640	and	_
22-12	3641-3644	the	_
22-13	3645-3658	Institutional	_
22-14	3659-3665	Review	_
22-15	3666-3671	Board	_
22-16	3672-3674	of	_
22-17	3675-3678	the	_
22-18	3679-3687	National	_
22-19	3688-3697	Institute	_
22-20	3698-3700	of	_
22-21	3701-3713	Radiological	_
22-22	3714-3722	Sciences	_
22-23	3723-3724	,	_
22-24	3725-3730	Japan	_
22-25	3731-3732	,	_
22-26	3733-3736	and	_
22-27	3737-3740	was	_
22-28	3741-3748	carried	_
22-29	3749-3752	out	_
22-30	3753-3755	in	_
22-31	3756-3766	accordance	_
22-32	3767-3771	with	_
22-33	3772-3775	the	_
22-34	3776-3780	Code	_
22-35	3781-3783	of	_
22-36	3784-3790	Ethics	_
22-37	3791-3793	of	_
22-38	3794-3797	the	_
22-39	3798-3803	World	_
22-40	3804-3811	Medical	_
22-41	3812-3823	Association	_
22-42	3824-3825	.	_

Text=After complete description of the study, written informed consent was obtained from all participants.
23-1	3826-3831	After	_
23-2	3832-3840	complete	_
23-3	3841-3852	description	_
23-4	3853-3855	of	_
23-5	3856-3859	the	_
23-6	3860-3865	study	_
23-7	3866-3867	,	_
23-8	3868-3875	written	_
23-9	3876-3884	informed	_
23-10	3885-3892	consent	_
23-11	3893-3896	was	_
23-12	3897-3905	obtained	_
23-13	3906-3910	from	_
23-14	3911-3914	all	_
23-15	3915-3927	participants	_
23-16	3928-3929	.	_

Text=Data were collected between April 2008 and October 2016.
24-1	3930-3934	Data	_
24-2	3935-3939	were	_
24-3	3940-3949	collected	_
24-4	3950-3957	between	_
24-5	3958-3963	April	_
24-6	3964-3968	2008	_
24-7	3969-3972	and	_
24-8	3973-3980	October	_
24-9	3981-3985	2016	_
24-10	3986-3987	.	_

Text=PET Procedures All subjects underwent 2 PET scans on the same day, one with [11C] raclopride and the other with [11C] MNPA, except 1 control subject who took the 2 scans on separate days due to technical trouble.
25-1	3988-3991	PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography
25-2	3992-4002	Procedures	_
25-3	4003-4006	All	_
25-4	4007-4015	subjects	_
25-5	4016-4025	underwent	_
25-6	4026-4027	2	_
25-7	4028-4031	PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography
25-8	4032-4037	scans	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography
25-9	4038-4040	on	_
25-10	4041-4044	the	_
25-11	4045-4049	same	_
25-12	4050-4053	day	_
25-13	4054-4055	,	_
25-14	4056-4059	one	_
25-15	4060-4064	with	_
25-16	4065-4066	[	_
25-17	4067-4070	11C	_
25-18	4071-4072	]	_
25-19	4073-4083	raclopride	_
25-20	4084-4087	and	_
25-21	4088-4091	the	_
25-22	4092-4097	other	_
25-23	4098-4102	with	_
25-24	4103-4104	[	_
25-25	4105-4108	11C	_
25-26	4109-4110	]	_
25-27	4111-4115	MNPA	_
25-28	4116-4117	,	_
25-29	4118-4124	except	_
25-30	4125-4126	1	_
25-31	4127-4134	control	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
25-32	4135-4142	subject	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
25-33	4143-4146	who	_
25-34	4147-4151	took	_
25-35	4152-4155	the	_
25-36	4156-4157	2	_
25-37	4158-4163	scans	_
25-38	4164-4166	on	_
25-39	4167-4175	separate	_
25-40	4176-4180	days	_
25-41	4181-4184	due	_
25-42	4185-4187	to	_
25-43	4188-4197	technical	_
25-44	4198-4205	trouble	_
25-45	4206-4207	.	_

Text=[11C] MNPA-PET preceded [11C] raclopride-PET in 10 patients and 11 controls, and [11C] raclopride-PET was followed by [11C] MNPA-PET in 1 patient and 6 controls.
26-1	4208-4209	[	_
26-2	4210-4213	11C	_
26-3	4214-4215	]	_
26-4	4216-4224	MNPA-PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography
26-5	4225-4233	preceded	_
26-6	4234-4235	[	_
26-7	4236-4239	11C	_
26-8	4240-4241	]	_
26-9	4242-4256	raclopride-PET	_
26-10	4257-4259	in	_
26-11	4260-4262	10	_
26-12	4263-4271	patients	_
26-13	4272-4275	and	_
26-14	4276-4278	11	_
26-15	4279-4287	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
26-16	4288-4289	,	_
26-17	4290-4293	and	_
26-18	4294-4295	[	_
26-19	4296-4299	11C	_
26-20	4300-4301	]	_
26-21	4302-4316	raclopride-PET	_
26-22	4317-4320	was	_
26-23	4321-4329	followed	_
26-24	4330-4332	by	_
26-25	4333-4334	[	_
26-26	4335-4338	11C	_
26-27	4339-4340	]	_
26-28	4341-4349	MNPA-PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography
26-29	4350-4352	in	_
26-30	4353-4354	1	_
26-31	4355-4362	patient	_
26-32	4363-4366	and	_
26-33	4367-4368	6	_
26-34	4369-4377	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
26-35	4378-4379	.	_

Text=After i.v.
27-1	4380-4385	After	_
27-2	4386-4389	i.v	_
27-3	4390-4391	.	_

Text=rapid bolus injection of [11C] raclopride, a PET scan was performed for 60 minutes.
28-1	4392-4397	rapid	_
28-2	4398-4403	bolus	_
28-3	4404-4413	injection	_
28-4	4414-4416	of	_
28-5	4417-4418	[	_
28-6	4419-4422	11C	_
28-7	4423-4424	]	_
28-8	4425-4435	raclopride	_
28-9	4436-4437	,	_
28-10	4438-4439	a	_
28-11	4440-4443	PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography
28-12	4444-4448	scan	_
28-13	4449-4452	was	_
28-14	4453-4462	performed	_
28-15	4463-4466	for	_
28-16	4467-4469	60	_
28-17	4470-4477	minutes	_
28-18	4478-4479	.	_

Text=Similarly, after i.v.
29-1	4480-4489	Similarly	_
29-2	4490-4491	,	_
29-3	4492-4497	after	_
29-4	4498-4501	i.v	_
29-5	4502-4503	.	_

Text=rapid bolus injection of [11C] MNPA, a PET scan was performed for 90 minutes.
30-1	4504-4509	rapid	_
30-2	4510-4515	bolus	_
30-3	4516-4525	injection	_
30-4	4526-4528	of	_
30-5	4529-4530	[	_
30-6	4531-4534	11C	_
30-7	4535-4536	]	_
30-8	4537-4541	MNPA	_
30-9	4542-4543	,	_
30-10	4544-4545	a	_
30-11	4546-4549	PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography
30-12	4550-4554	scan	_
30-13	4555-4558	was	_
30-14	4559-4568	performed	_
30-15	4569-4572	for	_
30-16	4573-4575	90	_
30-17	4576-4583	minutes	_
30-18	4584-4585	.	_

Text=The time interval between initiations of the first and second PET scans was 120 minutes or longer.
31-1	4586-4589	The	_
31-2	4590-4594	time	_
31-3	4595-4603	interval	_
31-4	4604-4611	between	_
31-5	4612-4623	initiations	_
31-6	4624-4626	of	_
31-7	4627-4630	the	_
31-8	4631-4636	first	_
31-9	4637-4640	and	_
31-10	4641-4647	second	_
31-11	4648-4651	PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography
31-12	4652-4657	scans	_
31-13	4658-4661	was	_
31-14	4662-4665	120	_
31-15	4666-4673	minutes	_
31-16	4674-4676	or	_
31-17	4677-4683	longer	_
31-18	4684-4685	.	_

Text=For both PET scans, 3-dimensional dynamic PET data were acquired with a Siemens ECAT Exact HR+ system (CTI/Siemens), which provides 63 sections with an axial field of view of 15.5 cm.
32-1	4686-4689	For	_
32-2	4690-4694	both	_
32-3	4695-4698	PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography
32-4	4699-4704	scans	_
32-5	4705-4706	,	_
32-6	4707-4720	3-dimensional	_
32-7	4721-4728	dynamic	_
32-8	4729-4732	PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography
32-9	4733-4737	data	_
32-10	4738-4742	were	_
32-11	4743-4751	acquired	_
32-12	4752-4756	with	_
32-13	4757-4758	a	_
32-14	4759-4766	Siemens	_
32-15	4767-4771	ECAT	_
32-16	4772-4777	Exact	_
32-17	4778-4781	HR+	_
32-18	4782-4788	system	_
32-19	4789-4790	(	_
32-20	4791-4802	CTI/Siemens	_
32-21	4803-4804	)	_
32-22	4805-4806	,	_
32-23	4807-4812	which	_
32-24	4813-4821	provides	_
32-25	4822-4824	63	_
32-26	4825-4833	sections	_
32-27	4834-4838	with	_
32-28	4839-4841	an	_
32-29	4842-4847	axial	_
32-30	4848-4853	field	_
32-31	4854-4856	of	_
32-32	4857-4861	view	_
32-33	4862-4864	of	_
32-34	4865-4869	15.5	_
32-35	4870-4872	cm	_
32-36	4873-4874	.	_

Text=PET images were reconstructed with a filtered back-projection method with corrections for attenuation and scatter.
33-1	4875-4878	PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography
33-2	4879-4885	images	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography
33-3	4886-4890	were	_
33-4	4891-4904	reconstructed	_
33-5	4905-4909	with	_
33-6	4910-4911	a	_
33-7	4912-4920	filtered	_
33-8	4921-4936	back-projection	_
33-9	4937-4943	method	_
33-10	4944-4948	with	_
33-11	4949-4960	corrections	_
33-12	4961-4964	for	_
33-13	4965-4976	attenuation	_
33-14	4977-4980	and	_
33-15	4981-4988	scatter	_
33-16	4989-4990	.	_

Text=The reconstructed in-plane resolution was 7.5 mm full-width at half-maximum.
34-1	4991-4994	The	_
34-2	4995-5008	reconstructed	_
34-3	5009-5017	in-plane	_
34-4	5018-5028	resolution	_
34-5	5029-5032	was	_
34-6	5033-5036	7.5	_
34-7	5037-5039	mm	_
34-8	5040-5050	full-width	_
34-9	5051-5053	at	_
34-10	5054-5066	half-maximum	_
34-11	5067-5068	.	_

Text=A 10-minute transmission scan using a 68Ge/68Ga line source was performed before each PET scan for attenuation correction.
35-1	5069-5070	A	_
35-2	5071-5080	10-minute	_
35-3	5081-5093	transmission	_
35-4	5094-5098	scan	_
35-5	5099-5104	using	_
35-6	5105-5106	a	_
35-7	5107-5116	68Ge/68Ga	_
35-8	5117-5121	line	_
35-9	5122-5128	source	_
35-10	5129-5132	was	_
35-11	5133-5142	performed	_
35-12	5143-5149	before	_
35-13	5150-5154	each	_
35-14	5155-5158	PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography
35-15	5159-5163	scan	_
35-16	5164-5167	for	_
35-17	5168-5179	attenuation	_
35-18	5180-5190	correction	_
35-19	5191-5192	.	_

Text=A thermoplastic head fixation device was used to minimize head movement during PET scanning.
36-1	5193-5194	A	_
36-2	5195-5208	thermoplastic	_
36-3	5209-5213	head	_
36-4	5214-5222	fixation	_
36-5	5223-5229	device	_
36-6	5230-5233	was	_
36-7	5234-5238	used	_
36-8	5239-5241	to	_
36-9	5242-5250	minimize	_
36-10	5251-5255	head	_
36-11	5256-5264	movement	_
36-12	5265-5271	during	_
36-13	5272-5275	PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography
36-14	5276-5284	scanning	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography
36-15	5285-5286	.	_

Text=The dynamic scans consisted of twelve 20-second frames, sixteen 60-second frames, and ten 240-second frames for [11C] raclopride, and nine 20-second frames, five 60-second frames, four 120-second frames, eleven 240-second frames, and six 300-second frames for [11C] MNPA.
37-1	5287-5290	The	_
37-2	5291-5298	dynamic	_
37-3	5299-5304	scans	_
37-4	5305-5314	consisted	_
37-5	5315-5317	of	_
37-6	5318-5324	twelve	_
37-7	5325-5334	20-second	_
37-8	5335-5341	frames	_
37-9	5342-5343	,	_
37-10	5344-5351	sixteen	_
37-11	5352-5361	60-second	_
37-12	5362-5368	frames	_
37-13	5369-5370	,	_
37-14	5371-5374	and	_
37-15	5375-5378	ten	_
37-16	5379-5389	240-second	_
37-17	5390-5396	frames	_
37-18	5397-5400	for	_
37-19	5401-5402	[	_
37-20	5403-5406	11C	_
37-21	5407-5408	]	_
37-22	5409-5419	raclopride	_
37-23	5420-5421	,	_
37-24	5422-5425	and	_
37-25	5426-5430	nine	_
37-26	5431-5440	20-second	_
37-27	5441-5447	frames	_
37-28	5448-5449	,	_
37-29	5450-5454	five	_
37-30	5455-5464	60-second	_
37-31	5465-5471	frames	_
37-32	5472-5473	,	_
37-33	5474-5478	four	_
37-34	5479-5489	120-second	_
37-35	5490-5496	frames	_
37-36	5497-5498	,	_
37-37	5499-5505	eleven	_
37-38	5506-5516	240-second	_
37-39	5517-5523	frames	_
37-40	5524-5525	,	_
37-41	5526-5529	and	_
37-42	5530-5533	six	_
37-43	5534-5544	300-second	_
37-44	5545-5551	frames	_
37-45	5552-5555	for	_
37-46	5556-5557	[	_
37-47	5558-5561	11C	_
37-48	5562-5563	]	_
37-49	5564-5568	MNPA	_
37-50	5569-5570	.	_

Text=MRI Procedures Because of replacements of MRI machines during this study, 3 types of MRI devices were used depending on the time of participant recruitment.
38-1	5571-5574	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
38-2	5575-5585	Procedures	_
38-3	5586-5593	Because	_
38-4	5594-5596	of	_
38-5	5597-5609	replacements	_
38-6	5610-5612	of	_
38-7	5613-5616	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
38-8	5617-5625	machines	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
38-9	5626-5632	during	_
38-10	5633-5637	this	_
38-11	5638-5643	study	_
38-12	5644-5645	,	_
38-13	5646-5647	3	_
38-14	5648-5653	types	_
38-15	5654-5656	of	_
38-16	5657-5660	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
38-17	5661-5668	devices	_
38-18	5669-5673	were	_
38-19	5674-5678	used	_
38-20	5679-5688	depending	_
38-21	5689-5691	on	_
38-22	5692-5695	the	_
38-23	5696-5700	time	_
38-24	5701-5703	of	_
38-25	5704-5715	participant	_
38-26	5716-5727	recruitment	_
38-27	5728-5729	.	_

Text=For the initial 4 patients and 7 controls, MR images were acquired with a 1.5-T MR scanner (Intera, Philips Medical Systems).
39-1	5730-5733	For	_
39-2	5734-5737	the	_
39-3	5738-5745	initial	_
39-4	5746-5747	4	_
39-5	5748-5756	patients	_
39-6	5757-5760	and	_
39-7	5761-5762	7	_
39-8	5763-5771	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
39-9	5772-5773	,	_
39-10	5774-5776	MR	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
39-11	5777-5783	images	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
39-12	5784-5788	were	_
39-13	5789-5797	acquired	_
39-14	5798-5802	with	_
39-15	5803-5804	a	_
39-16	5805-5810	1.5-T	_
39-17	5811-5813	MR	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
39-18	5814-5821	scanner	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
39-19	5822-5823	(	_
39-20	5824-5830	Intera	_
39-21	5831-5832	,	_
39-22	5833-5840	Philips	_
39-23	5841-5848	Medical	_
39-24	5849-5856	Systems	_
39-25	5857-5858	)	_
39-26	5859-5860	.	_

Text=3D volumetric acquisition of a T1-weighted gradient echo sequence produced a gapless series of thin transverse sections (TE 9.2 ms, TR 21 ms, flip angle 30°, field of view 256 mm, acquisition matrix 256 × 256, slice thickness 1 mm).
40-1	5861-5863	3D	_
40-2	5864-5874	volumetric	_
40-3	5875-5886	acquisition	_
40-4	5887-5889	of	_
40-5	5890-5891	a	_
40-6	5892-5903	T1-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
40-7	5904-5912	gradient	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
40-8	5913-5917	echo	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
40-9	5918-5926	sequence	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
40-10	5927-5935	produced	_
40-11	5936-5937	a	_
40-12	5938-5945	gapless	_
40-13	5946-5952	series	_
40-14	5953-5955	of	_
40-15	5956-5960	thin	_
40-16	5961-5971	transverse	_
40-17	5972-5980	sections	_
40-18	5981-5982	(	_
40-19	5983-5985	TE	_
40-20	5986-5989	9.2	_
40-21	5990-5992	ms	_
40-22	5993-5994	,	_
40-23	5995-5997	TR	_
40-24	5998-6000	21	_
40-25	6001-6003	ms	_
40-26	6004-6005	,	_
40-27	6006-6010	flip	_
40-28	6011-6016	angle	_
40-29	6017-6020	30°	_
40-30	6021-6022	,	_
40-31	6023-6028	field	_
40-32	6029-6031	of	_
40-33	6032-6036	view	_
40-34	6037-6040	256	_
40-35	6041-6043	mm	_
40-36	6044-6045	,	_
40-37	6046-6057	acquisition	_
40-38	6058-6064	matrix	_
40-39	6065-6068	256	_
40-40	6069-6070	×	_
40-41	6071-6074	256	_
40-42	6075-6076	,	_
40-43	6077-6082	slice	_
40-44	6083-6092	thickness	_
40-45	6093-6094	1	_
40-46	6095-6097	mm	_
40-47	6098-6099	)	_
40-48	6100-6101	.	_

Text=Then, for the next 6 patients, a 3-T MR scanner (Sigma HDx, General Electric) was used.
41-1	6102-6106	Then	_
41-2	6107-6108	,	_
41-3	6109-6112	for	_
41-4	6113-6116	the	_
41-5	6117-6121	next	_
41-6	6122-6123	6	_
41-7	6124-6132	patients	_
41-8	6133-6134	,	_
41-9	6135-6136	a	_
41-10	6137-6140	3-T	_
41-11	6141-6143	MR	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
41-12	6144-6151	scanner	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
41-13	6152-6153	(	_
41-14	6154-6159	Sigma	_
41-15	6160-6163	HDx	_
41-16	6164-6165	,	_
41-17	6166-6173	General	_
41-18	6174-6182	Electric	_
41-19	6183-6184	)	_
41-20	6185-6188	was	_
41-21	6189-6193	used	_
41-22	6194-6195	.	_

Text=3D volumetric acquisition of a T1-weighted 3-dimensional fast spoiled gradient-recalled acquisition in the steady-state sequence produced a gapless series of thin transverse sections (TE 2.8 ms, TR 7.0 ms, flip angle 8°, field of view 260 mm, acquisition matrix 256 × 256, slice thickness 1 mm).
42-1	6196-6198	3D	_
42-2	6199-6209	volumetric	_
42-3	6210-6221	acquisition	_
42-4	6222-6224	of	_
42-5	6225-6226	a	_
42-6	6227-6238	T1-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
42-7	6239-6252	3-dimensional	_
42-8	6253-6257	fast	_
42-9	6258-6265	spoiled	_
42-10	6266-6283	gradient-recalled	_
42-11	6284-6295	acquisition	_
42-12	6296-6298	in	_
42-13	6299-6302	the	_
42-14	6303-6315	steady-state	_
42-15	6316-6324	sequence	_
42-16	6325-6333	produced	_
42-17	6334-6335	a	_
42-18	6336-6343	gapless	_
42-19	6344-6350	series	_
42-20	6351-6353	of	_
42-21	6354-6358	thin	_
42-22	6359-6369	transverse	_
42-23	6370-6378	sections	_
42-24	6379-6380	(	_
42-25	6381-6383	TE	_
42-26	6384-6387	2.8	_
42-27	6388-6390	ms	_
42-28	6391-6392	,	_
42-29	6393-6395	TR	_
42-30	6396-6399	7.0	_
42-31	6400-6402	ms	_
42-32	6403-6404	,	_
42-33	6405-6409	flip	_
42-34	6410-6415	angle	_
42-35	6416-6418	8°	_
42-36	6419-6420	,	_
42-37	6421-6426	field	_
42-38	6427-6429	of	_
42-39	6430-6434	view	_
42-40	6435-6438	260	_
42-41	6439-6441	mm	_
42-42	6442-6443	,	_
42-43	6444-6455	acquisition	_
42-44	6456-6462	matrix	_
42-45	6463-6466	256	_
42-46	6467-6468	×	_
42-47	6469-6472	256	_
42-48	6473-6474	,	_
42-49	6475-6480	slice	_
42-50	6481-6490	thickness	_
42-51	6491-6492	1	_
42-52	6493-6495	mm	_
42-53	6496-6497	)	_
42-54	6498-6499	.	_

Text=Finally, for 1 patient and 10 controls, T1-weighted MR images were obtained with another 3-T MR scanner (MAGNETOM Verio, Siemens).
43-1	6500-6507	Finally	_
43-2	6508-6509	,	_
43-3	6510-6513	for	_
43-4	6514-6515	1	_
43-5	6516-6523	patient	_
43-6	6524-6527	and	_
43-7	6528-6530	10	_
43-8	6531-6539	controls	_
43-9	6540-6541	,	_
43-10	6542-6553	T1-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
43-11	6554-6556	MR	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
43-12	6557-6563	images	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
43-13	6564-6568	were	_
43-14	6569-6577	obtained	_
43-15	6578-6582	with	_
43-16	6583-6590	another	_
43-17	6591-6594	3-T	_
43-18	6595-6597	MR	_
43-19	6598-6605	scanner	_
43-20	6606-6607	(	_
43-21	6608-6616	MAGNETOM	_
43-22	6617-6622	Verio	_
43-23	6623-6624	,	_
43-24	6625-6632	Siemens	_
43-25	6633-6634	)	_
43-26	6635-6636	.	_

Text=3D volumetric acquisition of a T1-weighted gradient echo sequence produced a gapless series of thin sagittal sections (TE 1.95 ms, TR 2300 ms, TI 900 ms, flip angle 9°, field of view 250 mm, acquisition matrix 256×256, slice thickness 1 mm).
44-1	6637-6639	3D	_
44-2	6640-6650	volumetric	_
44-3	6651-6662	acquisition	_
44-4	6663-6665	of	_
44-5	6666-6667	a	_
44-6	6668-6679	T1-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
44-7	6680-6688	gradient	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
44-8	6689-6693	echo	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
44-9	6694-6702	sequence	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
44-10	6703-6711	produced	_
44-11	6712-6713	a	_
44-12	6714-6721	gapless	_
44-13	6722-6728	series	_
44-14	6729-6731	of	_
44-15	6732-6736	thin	_
44-16	6737-6745	sagittal	_
44-17	6746-6754	sections	_
44-18	6755-6756	(	_
44-19	6757-6759	TE	_
44-20	6760-6764	1.95	_
44-21	6765-6767	ms	_
44-22	6768-6769	,	_
44-23	6770-6772	TR	_
44-24	6773-6777	2300	_
44-25	6778-6780	ms	_
44-26	6781-6782	,	_
44-27	6783-6785	TI	_
44-28	6786-6789	900	_
44-29	6790-6792	ms	_
44-30	6793-6794	,	_
44-31	6795-6799	flip	_
44-32	6800-6805	angle	_
44-33	6806-6808	9°	_
44-34	6809-6810	,	_
44-35	6811-6816	field	_
44-36	6817-6819	of	_
44-37	6820-6824	view	_
44-38	6825-6828	250	_
44-39	6829-6831	mm	_
44-40	6832-6833	,	_
44-41	6834-6845	acquisition	_
44-42	6846-6852	matrix	_
44-43	6853-6860	256×256	_
44-44	6861-6862	,	_
44-45	6863-6868	slice	_
44-46	6869-6878	thickness	_
44-47	6879-6880	1	_
44-48	6881-6883	mm	_
44-49	6884-6885	)	_
44-50	6886-6887	.	_

Text=Region of Interest (ROI) Definition All ROIs used in our analyses were initially defined on a standard anatomic orientation (MNI standard space; Montreal Neurological Institute).
45-1	6888-6894	Region	_
45-2	6895-6897	of	_
45-3	6898-6906	Interest	_
45-4	6907-6908	(	_
45-5	6909-6912	ROI	_
45-6	6913-6914	)	_
45-7	6915-6925	Definition	_
45-8	6926-6929	All	_
45-9	6930-6934	ROIs	_
45-10	6935-6939	used	_
45-11	6940-6942	in	_
45-12	6943-6946	our	_
45-13	6947-6955	analyses	_
45-14	6956-6960	were	_
45-15	6961-6970	initially	_
45-16	6971-6978	defined	_
45-17	6979-6981	on	_
45-18	6982-6983	a	_
45-19	6984-6992	standard	_
45-20	6993-7001	anatomic	_
45-21	7002-7013	orientation	_
45-22	7014-7015	(	_
45-23	7016-7019	MNI	_
45-24	7020-7028	standard	_
45-25	7029-7034	space	_
45-26	7035-7036	;	_
45-27	7037-7045	Montreal	_
45-28	7046-7058	Neurological	_
45-29	7059-7068	Institute	_
45-30	7069-7070	)	_
45-31	7071-7072	.	_

Text=Striatum ROIs (caudate, putamen, and ventral striata) were defined using a striatum anatomical atlas.
46-1	7073-7081	Striatum	_
46-2	7082-7086	ROIs	_
46-3	7087-7088	(	_
46-4	7089-7096	caudate	_
46-5	7097-7098	,	_
46-6	7099-7106	putamen	_
46-7	7107-7108	,	_
46-8	7109-7112	and	_
46-9	7113-7120	ventral	_
46-10	7121-7128	striata	_
46-11	7129-7130	)	_
46-12	7131-7135	were	_
46-13	7136-7143	defined	_
46-14	7144-7149	using	_
46-15	7150-7151	a	_
46-16	7152-7160	striatum	_
46-17	7161-7171	anatomical	_
46-18	7172-7177	atlas	_
46-19	7178-7179	.	_

Text=A cerebellum ROI was defined with a probabilistic cerebellar atlas, excluding the vermis.
47-1	7180-7181	A	_
47-2	7182-7192	cerebellum	_
47-3	7193-7196	ROI	_
47-4	7197-7200	was	_
47-5	7201-7208	defined	_
47-6	7209-7213	with	_
47-7	7214-7215	a	_
47-8	7216-7229	probabilistic	_
47-9	7230-7240	cerebellar	_
47-10	7241-7246	atlas	_
47-11	7247-7248	,	_
47-12	7249-7258	excluding	_
47-13	7259-7262	the	_
47-14	7263-7269	vermis	_
47-15	7270-7271	.	_

Text=These ROIs were transformed into individual MR spaces with transformation matrices calculated with the “ normalize ” function of statistical parametric mapping software (SPM12; Wellcome Department of Imaging Neuroscience) and were thresholded using FreeSurfer ’ s automated anatomical segmentation to exclude neighboring white matter, ventricles, and non-brain regions.
48-1	7272-7277	These	_
48-2	7278-7282	ROIs	_
48-3	7283-7287	were	_
48-4	7288-7299	transformed	_
48-5	7300-7304	into	_
48-6	7305-7315	individual	_
48-7	7316-7318	MR	_
48-8	7319-7325	spaces	_
48-9	7326-7330	with	_
48-10	7331-7345	transformation	_
48-11	7346-7354	matrices	_
48-12	7355-7365	calculated	_
48-13	7366-7370	with	_
48-14	7371-7374	the	_
48-15	7375-7376	“	_
48-16	7377-7386	normalize	_
48-17	7387-7388	”	_
48-18	7389-7397	function	_
48-19	7398-7400	of	_
48-20	7401-7412	statistical	_
48-21	7413-7423	parametric	_
48-22	7424-7431	mapping	_
48-23	7432-7440	software	_
48-24	7441-7442	(	_
48-25	7443-7448	SPM12	_
48-26	7449-7450	;	_
48-27	7451-7459	Wellcome	_
48-28	7460-7470	Department	_
48-29	7471-7473	of	_
48-30	7474-7481	Imaging	_
48-31	7482-7494	Neuroscience	_
48-32	7495-7496	)	_
48-33	7497-7500	and	_
48-34	7501-7505	were	_
48-35	7506-7517	thresholded	_
48-36	7518-7523	using	_
48-37	7524-7534	FreeSurfer	_
48-38	7535-7536	’	_
48-39	7537-7538	s	_
48-40	7539-7548	automated	_
48-41	7549-7559	anatomical	_
48-42	7560-7572	segmentation	_
48-43	7573-7575	to	_
48-44	7576-7583	exclude	_
48-45	7584-7595	neighboring	_
48-46	7596-7601	white	_
48-47	7602-7608	matter	_
48-48	7609-7610	,	_
48-49	7611-7621	ventricles	_
48-50	7622-7623	,	_
48-51	7624-7627	and	_
48-52	7628-7637	non-brain	_
48-53	7638-7645	regions	_
48-54	7646-7647	.	_

Text=Time-activity curves for each ROI were extracted by applying these ROIs to individual dynamic PET images based on the transformation parameters for the coregistration of MR images to the PET spaces using PMOD software ver.
49-1	7648-7661	Time-activity	_
49-2	7662-7668	curves	_
49-3	7669-7672	for	_
49-4	7673-7677	each	_
49-5	7678-7681	ROI	_
49-6	7682-7686	were	_
49-7	7687-7696	extracted	_
49-8	7697-7699	by	_
49-9	7700-7708	applying	_
49-10	7709-7714	these	_
49-11	7715-7719	ROIs	_
49-12	7720-7722	to	_
49-13	7723-7733	individual	_
49-14	7734-7741	dynamic	_
49-15	7742-7745	PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography
49-16	7746-7752	images	_
49-17	7753-7758	based	_
49-18	7759-7761	on	_
49-19	7762-7765	the	_
49-20	7766-7780	transformation	_
49-21	7781-7791	parameters	_
49-22	7792-7795	for	_
49-23	7796-7799	the	_
49-24	7800-7814	coregistration	_
49-25	7815-7817	of	_
49-26	7818-7820	MR	_
49-27	7821-7827	images	_
49-28	7828-7830	to	_
49-29	7831-7834	the	_
49-30	7835-7838	PET	_
49-31	7839-7845	spaces	_
49-32	7846-7851	using	_
49-33	7852-7856	PMOD	_
49-34	7857-7865	software	_
49-35	7866-7869	ver	_
49-36	7870-7871	.	_

Text=3.7 (PMOD Technologies Ltd).
50-1	7872-7875	3.7	_
50-2	7876-7877	(	_
50-3	7878-7882	PMOD	_
50-4	7883-7895	Technologies	_
50-5	7896-7899	Ltd	_
50-6	7900-7901	)	_
50-7	7902-7903	.	_

Text=Quantification of Total D2R and D2High Availabilities in the Striatum Availabilities of striatal total D2R and D2High were quantified as binding potentials relative to the nondisplaceable tissue (BPND) of [11C] raclopride and [11C] MNPA, respectively.
51-1	7904-7918	Quantification	_
51-2	7919-7921	of	_
51-3	7922-7927	Total	_
51-4	7928-7931	D2R	_
51-5	7932-7935	and	_
51-6	7936-7942	D2High	_
51-7	7943-7957	Availabilities	_
51-8	7958-7960	in	_
51-9	7961-7964	the	_
51-10	7965-7973	Striatum	_
51-11	7974-7988	Availabilities	_
51-12	7989-7991	of	_
51-13	7992-8000	striatal	_
51-14	8001-8006	total	_
51-15	8007-8010	D2R	_
51-16	8011-8014	and	_
51-17	8015-8021	D2High	_
51-18	8022-8026	were	_
51-19	8027-8037	quantified	_
51-20	8038-8040	as	_
51-21	8041-8048	binding	_
51-22	8049-8059	potentials	_
51-23	8060-8068	relative	_
51-24	8069-8071	to	_
51-25	8072-8075	the	_
51-26	8076-8091	nondisplaceable	_
51-27	8092-8098	tissue	_
51-28	8099-8100	(	_
51-29	8101-8105	BPND	_
51-30	8106-8107	)	_
51-31	8108-8110	of	_
51-32	8111-8112	[	_
51-33	8113-8116	11C	_
51-34	8117-8118	]	_
51-35	8119-8129	raclopride	_
51-36	8130-8133	and	_
51-37	8134-8135	[	_
51-38	8136-8139	11C	_
51-39	8140-8141	]	_
51-40	8142-8146	MNPA	_
51-41	8147-8148	,	_
51-42	8149-8161	respectively	_
51-43	8162-8163	.	_

Text=[11C] raclopride BPND and [11C] MNPA BPND were calculated for each ROI using a 3-parameter simplified reference tissue model and cerebellar cortex as reference tissue, which has negligible density of D2R.
52-1	8164-8165	[	_
52-2	8166-8169	11C	_
52-3	8170-8171	]	_
52-4	8172-8182	raclopride	_
52-5	8183-8187	BPND	_
52-6	8188-8191	and	_
52-7	8192-8193	[	_
52-8	8194-8197	11C	_
52-9	8198-8199	]	_
52-10	8200-8204	MNPA	_
52-11	8205-8209	BPND	_
52-12	8210-8214	were	_
52-13	8215-8225	calculated	_
52-14	8226-8229	for	_
52-15	8230-8234	each	_
52-16	8235-8238	ROI	_
52-17	8239-8244	using	_
52-18	8245-8246	a	_
52-19	8247-8258	3-parameter	_
52-20	8259-8269	simplified	_
52-21	8270-8279	reference	_
52-22	8280-8286	tissue	_
52-23	8287-8292	model	_
52-24	8293-8296	and	_
52-25	8297-8307	cerebellar	_
52-26	8308-8314	cortex	_
52-27	8315-8317	as	_
52-28	8318-8327	reference	_
52-29	8328-8334	tissue	_
52-30	8335-8336	,	_
52-31	8337-8342	which	_
52-32	8343-8346	has	_
52-33	8347-8357	negligible	_
52-34	8358-8365	density	_
52-35	8366-8368	of	_
52-36	8369-8372	D2R	_
52-37	8373-8374	.	_

Text=BPND was defined as follows: where fND is the free fraction of radioligand in the nondisplaceable tissue compartment and Bavail indicates the neuroreceptor density.
53-1	8375-8379	BPND	_
53-2	8380-8383	was	_
53-3	8384-8391	defined	_
53-4	8392-8394	as	_
53-5	8395-8402	follows	_
53-6	8403-8404	:	_
53-7	8405-8410	where	_
53-8	8411-8414	fND	_
53-9	8415-8417	is	_
53-10	8418-8421	the	_
53-11	8422-8426	free	_
53-12	8427-8435	fraction	_
53-13	8436-8438	of	_
53-14	8439-8450	radioligand	_
53-15	8451-8453	in	_
53-16	8454-8457	the	_
53-17	8458-8473	nondisplaceable	_
53-18	8474-8480	tissue	_
53-19	8481-8492	compartment	_
53-20	8493-8496	and	_
53-21	8497-8503	Bavail	_
53-22	8504-8513	indicates	_
53-23	8514-8517	the	_
53-24	8518-8531	neuroreceptor	_
53-25	8532-8539	density	_
53-26	8540-8541	.	_

Text=All kinetic analyses were performed using PMOD software ver.
54-1	8542-8545	All	_
54-2	8546-8553	kinetic	_
54-3	8554-8562	analyses	_
54-4	8563-8567	were	_
54-5	8568-8577	performed	_
54-6	8578-8583	using	_
54-7	8584-8588	PMOD	_
54-8	8589-8597	software	_
54-9	8598-8601	ver	_
54-10	8602-8603	.	_

Text=3.7.
55-1	8604-8607	3.7	_
55-2	8608-8609	.	_

Text=Statistical Analysis Statistical analyses were conducted with SPSS 23.0 (SPSS Inc).
56-1	8610-8621	Statistical	_
56-2	8622-8630	Analysis	_
56-3	8631-8642	Statistical	_
56-4	8643-8651	analyses	_
56-5	8652-8656	were	_
56-6	8657-8666	conducted	_
56-7	8667-8671	with	_
56-8	8672-8676	SPSS	_
56-9	8677-8681	23.0	_
56-10	8682-8683	(	_
56-11	8684-8688	SPSS	_
56-12	8689-8692	Inc	_
56-13	8693-8694	)	_
56-14	8695-8696	.	_

Text=First, MANCOVA was applied to examine group differences in: (1) BPND of [11C] raclopride; (2) BPND of [11C] MNPA; and (3) the BPND ratio (ratio of [11C] MNPA BPND to [11C] raclopride BPND) in 3 striatal ROIs (caudate, putamen, and ventral striata), separately.
57-1	8697-8702	First	_
57-2	8703-8704	,	_
57-3	8705-8712	MANCOVA	_
57-4	8713-8716	was	_
57-5	8717-8724	applied	_
57-6	8725-8727	to	_
57-7	8728-8735	examine	_
57-8	8736-8741	group	_
57-9	8742-8753	differences	_
57-10	8754-8756	in	_
57-11	8757-8758	:	_
57-12	8759-8760	(	_
57-13	8761-8762	1	_
57-14	8763-8764	)	_
57-15	8765-8769	BPND	_
57-16	8770-8772	of	_
57-17	8773-8774	[	_
57-18	8775-8778	11C	_
57-19	8779-8780	]	_
57-20	8781-8791	raclopride	_
57-21	8792-8793	;	_
57-22	8794-8795	(	_
57-23	8796-8797	2	_
57-24	8798-8799	)	_
57-25	8800-8804	BPND	_
57-26	8805-8807	of	_
57-27	8808-8809	[	_
57-28	8810-8813	11C	_
57-29	8814-8815	]	_
57-30	8816-8820	MNPA	_
57-31	8821-8822	;	_
57-32	8823-8826	and	_
57-33	8827-8828	(	_
57-34	8829-8830	3	_
57-35	8831-8832	)	_
57-36	8833-8836	the	_
57-37	8837-8841	BPND	_
57-38	8842-8847	ratio	_
57-39	8848-8849	(	_
57-40	8850-8855	ratio	_
57-41	8856-8858	of	_
57-42	8859-8860	[	_
57-43	8861-8864	11C	_
57-44	8865-8866	]	_
57-45	8867-8871	MNPA	_
57-46	8872-8876	BPND	_
57-47	8877-8879	to	_
57-48	8880-8881	[	_
57-49	8882-8885	11C	_
57-50	8886-8887	]	_
57-51	8888-8898	raclopride	_
57-52	8899-8903	BPND	_
57-53	8904-8905	)	_
57-54	8906-8908	in	_
57-55	8909-8910	3	_
57-56	8911-8919	striatal	_
57-57	8920-8924	ROIs	_
57-58	8925-8926	(	_
57-59	8927-8934	caudate	_
57-60	8935-8936	,	_
57-61	8937-8944	putamen	_
57-62	8945-8946	,	_
57-63	8947-8950	and	_
57-64	8951-8958	ventral	_
57-65	8959-8966	striata	_
57-66	8967-8968	)	_
57-67	8969-8970	,	_
57-68	8971-8981	separately	_
57-69	8982-8983	.	_

Text=A fixed factor was diagnosis (patients = 1, controls = 0).
58-1	8984-8985	A	_
58-2	8986-8991	fixed	_
58-3	8992-8998	factor	_
58-4	8999-9002	was	_
58-5	9003-9012	diagnosis	_
58-6	9013-9014	(	_
58-7	9015-9023	patients	_
58-8	9024-9025	=	_
58-9	9026-9027	1	_
58-10	9028-9029	,	_
58-11	9030-9038	controls	_
58-12	9039-9040	=	_
58-13	9041-9042	0	_
58-14	9043-9044	)	_
58-15	9045-9046	.	_

Text=Nuisance covariates were defined as age, gender, and smoking state (smoker = 1, nonsmoker = 0) to control for their potential effects on D2Rs.
59-1	9047-9055	Nuisance	_
59-2	9056-9066	covariates	_
59-3	9067-9071	were	_
59-4	9072-9079	defined	_
59-5	9080-9082	as	_
59-6	9083-9086	age	_
59-7	9087-9088	,	_
59-8	9089-9095	gender	_
59-9	9096-9097	,	_
59-10	9098-9101	and	_
59-11	9102-9109	smoking	_
59-12	9110-9115	state	_
59-13	9116-9117	(	_
59-14	9118-9124	smoker	_
59-15	9125-9126	=	_
59-16	9127-9128	1	_
59-17	9129-9130	,	_
59-18	9131-9140	nonsmoker	_
59-19	9141-9142	=	_
59-20	9143-9144	0	_
59-21	9145-9146	)	_
59-22	9147-9149	to	_
59-23	9150-9157	control	_
59-24	9158-9161	for	_
59-25	9162-9167	their	_
59-26	9168-9177	potential	_
59-27	9178-9185	effects	_
59-28	9186-9188	on	_
59-29	9189-9193	D2Rs	_
59-30	9194-9195	.	_

Text=Statistical significance threshold was defined as P <.05 (2-tailed).
60-1	9196-9207	Statistical	_
60-2	9208-9220	significance	_
60-3	9221-9230	threshold	_
60-4	9231-9234	was	_
60-5	9235-9242	defined	_
60-6	9243-9245	as	_
60-7	9246-9247	P	_
60-8	9248-9249	<	_
60-9	9250-9253	.05	_
60-10	9254-9255	(	_
60-11	9256-9264	2-tailed	_
60-12	9265-9266	)	_
60-13	9267-9268	.	_

Text=Second, correlational analyses were performed between the BPND values mentioned above and each of the PANSS factor scores (positive, negative, disorganized/concrete, excited, and depressed factors) in patients.
61-1	9269-9275	Second	_
61-2	9276-9277	,	_
61-3	9278-9291	correlational	_
61-4	9292-9300	analyses	_
61-5	9301-9305	were	_
61-6	9306-9315	performed	_
61-7	9316-9323	between	_
61-8	9324-9327	the	_
61-9	9328-9332	BPND	_
61-10	9333-9339	values	_
61-11	9340-9349	mentioned	_
61-12	9350-9355	above	_
61-13	9356-9359	and	_
61-14	9360-9364	each	_
61-15	9365-9367	of	_
61-16	9368-9371	the	_
61-17	9372-9377	PANSS	_
61-18	9378-9384	factor	_
61-19	9385-9391	scores	_
61-20	9392-9393	(	_
61-21	9394-9402	positive	_
61-22	9403-9404	,	_
61-23	9405-9413	negative	_
61-24	9414-9415	,	_
61-25	9416-9437	disorganized/concrete	_
61-26	9438-9439	,	_
61-27	9440-9447	excited	_
61-28	9448-9449	,	_
61-29	9450-9453	and	_
61-30	9454-9463	depressed	_
61-31	9464-9471	factors	_
61-32	9472-9473	)	_
61-33	9474-9476	in	_
61-34	9477-9485	patients	_
61-35	9486-9487	.	_

Text=The statistical threshold was set at P <.05 with Bonferroni correction for the 3 striatal subregions (caudate, putamen, and ventral striata), as in previous studies.
62-1	9488-9491	The	_
62-2	9492-9503	statistical	_
62-3	9504-9513	threshold	_
62-4	9514-9517	was	_
62-5	9518-9521	set	_
62-6	9522-9524	at	_
62-7	9525-9526	P	_
62-8	9527-9528	<	_
62-9	9529-9532	.05	_
62-10	9533-9537	with	_
62-11	9538-9548	Bonferroni	_
62-12	9549-9559	correction	_
62-13	9560-9563	for	_
62-14	9564-9567	the	_
62-15	9568-9569	3	_
62-16	9570-9578	striatal	_
62-17	9579-9589	subregions	_
62-18	9590-9591	(	_
62-19	9592-9599	caudate	_
62-20	9600-9601	,	_
62-21	9602-9609	putamen	_
62-22	9610-9611	,	_
62-23	9612-9615	and	_
62-24	9616-9623	ventral	_
62-25	9624-9631	striata	_
62-26	9632-9633	)	_
62-27	9634-9635	,	_
62-28	9636-9638	as	_
62-29	9639-9641	in	_
62-30	9642-9650	previous	_
62-31	9651-9658	studies	_
62-32	9659-9660	.	_

Text=Because of the small sample size and exploratory nature of this study, corrections were not applied for multiple comparisons of the 5 PANSS factor scores and the 3 binding parameters ([11C] raclopride BPND, [11C] MNPA BPND, and their ratio).
63-1	9661-9668	Because	_
63-2	9669-9671	of	_
63-3	9672-9675	the	_
63-4	9676-9681	small	_
63-5	9682-9688	sample	_
63-6	9689-9693	size	_
63-7	9694-9697	and	_
63-8	9698-9709	exploratory	_
63-9	9710-9716	nature	_
63-10	9717-9719	of	_
63-11	9720-9724	this	_
63-12	9725-9730	study	_
63-13	9731-9732	,	_
63-14	9733-9744	corrections	_
63-15	9745-9749	were	_
63-16	9750-9753	not	_
63-17	9754-9761	applied	_
63-18	9762-9765	for	_
63-19	9766-9774	multiple	_
63-20	9775-9786	comparisons	_
63-21	9787-9789	of	_
63-22	9790-9793	the	_
63-23	9794-9795	5	_
63-24	9796-9801	PANSS	_
63-25	9802-9808	factor	_
63-26	9809-9815	scores	_
63-27	9816-9819	and	_
63-28	9820-9823	the	_
63-29	9824-9825	3	_
63-30	9826-9833	binding	_
63-31	9834-9844	parameters	_
63-32	9845-9846	(	_
63-33	9847-9848	[	_
63-34	9849-9852	11C	_
63-35	9853-9854	]	_
63-36	9855-9865	raclopride	_
63-37	9866-9870	BPND	_
63-38	9871-9872	,	_
63-39	9873-9874	[	_
63-40	9875-9878	11C	_
63-41	9879-9880	]	_
63-42	9881-9885	MNPA	_
63-43	9886-9890	BPND	_
63-44	9891-9892	,	_
63-45	9893-9896	and	_
63-46	9897-9902	their	_
63-47	9903-9908	ratio	_
63-48	9909-9910	)	_
63-49	9911-9912	.	_

Text=In case significant correlations were found, partial correlation analyses were also performed, controlling for age, gender, smoking state, or duration of illness.
64-1	9913-9915	In	_
64-2	9916-9920	case	_
64-3	9921-9932	significant	_
64-4	9933-9945	correlations	_
64-5	9946-9950	were	_
64-6	9951-9956	found	_
64-7	9957-9958	,	_
64-8	9959-9966	partial	_
64-9	9967-9978	correlation	_
64-10	9979-9987	analyses	_
64-11	9988-9992	were	_
64-12	9993-9997	also	_
64-13	9998-10007	performed	_
64-14	10008-10009	,	_
64-15	10010-10021	controlling	_
64-16	10022-10025	for	_
64-17	10026-10029	age	_
64-18	10030-10031	,	_
64-19	10032-10038	gender	_
64-20	10039-10040	,	_
64-21	10041-10048	smoking	_
64-22	10049-10054	state	_
64-23	10055-10056	,	_
64-24	10057-10059	or	_
64-25	10060-10068	duration	_
64-26	10069-10071	of	_
64-27	10072-10079	illness	_
64-28	10080-10081	.	_

Text=Statistical significance threshold was defined as P <.05 (2-tailed).
65-1	10082-10093	Statistical	_
65-2	10094-10106	significance	_
65-3	10107-10116	threshold	_
65-4	10117-10120	was	_
65-5	10121-10128	defined	_
65-6	10129-10131	as	_
65-7	10132-10133	P	_
65-8	10134-10135	<	_
65-9	10136-10139	.05	_
65-10	10140-10141	(	_
65-11	10142-10150	2-tailed	_
65-12	10151-10152	)	_
65-13	10153-10154	.	_

